Your browser doesn't support javascript.
loading
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Recondo, Gonzalo; Bahcall, Magda; Spurr, Liam F; Che, Jianwei; Ricciuti, Biagio; Leonardi, Giulia C; Lo, Ying-Chun; Li, Yvonne Y; Lamberti, Giuseppe; Nguyen, Tom; Milan, Marina S D; Venkatraman, Deepti; Umeton, Renato; Paweletz, Cloud P; Albayrak, Adem; Cherniack, Andrew D; Price, Kristin S; Fairclough, Stephen R; Nishino, Mizuki; Sholl, Lynette M; Oxnard, Geoffrey R; Jänne, Pasi A; Awad, Mark M.
Afiliação
  • Recondo G; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Bahcall M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Spurr LF; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Che J; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ricciuti B; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Leonardi GC; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Lo YC; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Li YY; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Lamberti G; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Nguyen T; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Milan MSD; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Venkatraman D; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Umeton R; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Paweletz CP; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Albayrak A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Cherniack AD; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Price KS; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Fairclough SR; Massachusetts Institute of Technology, Cambridge, Massachusetts.
  • Nishino M; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Sholl LM; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Oxnard GR; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Jänne PA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Awad MM; Guardant Health, Redwood City, California.
Clin Cancer Res ; 26(11): 2615-2625, 2020 06 01.
Article em En | MEDLINE | ID: mdl-32034073
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Éxons / Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Proteínas Proto-Oncogênicas c-met / Inibidores de Proteínas Quinases / Mutação Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Éxons / Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Proteínas Proto-Oncogênicas c-met / Inibidores de Proteínas Quinases / Mutação Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article